India is a very magical country.

As a major producer of generic drugs, India exports drugs to more than 200 countries, accounting for about 20% of the global market share.

India has nearly 3,000 generic drug companies, and India occupies two of the world's top seven generic drug companies.

Generic drugs in India are not only large in scale, low in price, but also reliable in quality.

From common cold medicines to targeted anti-cancer drugs, India can copy them.

Moreover, India's vaccine imitation ability is also excellent. India is the world's largest vaccine producer. However, it should be noted that India is not an excellent vaccine research and development country, and all the vaccines produced by India are imitated.

The prosperity of the generic drug industry has brought India the honorary title of world pharmacies.

Even in the United States, 40% of generic drugs are imported from India.

After all, although Indian generic drugs have affected the cheese of American pharmaceutical giants, they will not touch the interests of all Americans.

Due to the emergence of generic drugs, the medical costs of the middle and lower classes in the United States have also been greatly saved, which has led to the US government having no reason to sanction India's generic drugs.

And to the bottom of this, generic drugs were the first Americans to do this. If you have to settle the whole story, the Americans themselves are not clean.

The price of generic drugs in India is one-tenth of that of patented drugs, but the effect is almost comparable, and people from any country cannot refuse it.

The most sarcastic thing is that India's generic drug path is so developed thanks to the Indian government.

India's patent law stipulates that only process patents are granted for food and medicine, but not product patents, which means that India has abandoned the intellectual property protection of drug compounds.

In addition, the Indian government not only does not protect drug patents, but also compulsory licenses Indian pharmaceutical companies to copy patented drugs from multinational pharmaceutical companies.

Moreover, when India's generic drugs were developed, India had not yet joined the World Trade Organization and was not bound by international patent law.

Although India later joined the WTO, the generic drugs in India had developed for seventy or eighty years at that time, and had long formed a mature system and a very large scale.

Even though the WTO gave India a ten-year transition period of "protected pharmaceutical products", this transition period not only did not restrict India's generic drug market, but instead accelerated the pace of Indian generic drugs entering the international market...

Moreover, these generic drugs in India have their own explanations when they are openly infringed.

As long as multinational pharmaceutical companies condemn Indian pharmaceutical factories this way, they will say that most of these drugs are life-saving drugs. Should the poor be waiting to die because the medicine is too expensive?

This approach of standing on the commanding heights of morality makes European and American pharmaceutical companies not dare to ignore moral pressure and sue generic drug companies.

In contrast, like India, China, which has the advantages of manufacturing industry such as low manufacturing costs, simple operation technology, and high labor intensity, has failed to catch up with the pace of internationalization due to the slow start of pharmaceutical factories.

Moreover, after the pharmaceutical giant had already suffered losses from India, it registered a drug patent in China early.

The Chinese government cannot bear the slightest face, just like the Indian government, and still needs to maintain intellectual property rights, so Chinese pharmaceutical companies cannot produce generic drugs as unscrupulously as India, and can only copy some drugs that have been protected beyond the patent period.

In India, the decades of imitating advanced drugs from European and American pharmaceutical companies have also allowed them to gradually accumulate strong technology.

Whether it is pharmaceuticals or vaccine production, the technical level of Indian pharmaceutical factories is world-class, but they are just unwilling to invest money to develop new drugs themselves, which is outrageous!

Nowadays, the investment in drug research and development is getting higher and higher. On average, it takes about ten years to develop a new drug, and only one billion US dollars can it be developed.

After research and development, because the R&D cost is high, the unit price of the drug will naturally be high. If there is no considerable profit, which pharmaceutical company will take this risk?

Under normal circumstances, after a new drug has been spent in ten to twenty years of patent protection period, various pharmaceutical factories will start to imitate it, and the price can be reduced to a relatively low price.

In this way, the original pharmaceutical companies also make money and make profits, they can continue to develop the next drug. Some generic drug manufacturers can also make money by copying drugs, and patients can also use cheap drugs later.

These imitation pharmaceutical factories do not have the ability to imitate and sell them in advance, but they follow the patent law and the laws of sustainable development of the pharmaceutical industry and do not do such things as killing chickens and retrieving eggs.

However, Indians do not play according to common sense. Original pharmaceutical companies in Europe and the United States spent more than one billion US dollars to develop a new drug. They just registered their patents and were sold for a year or two before they sold them. Indian pharmaceutical companies used mandatory patent authorization to start producing generic drugs.

Then the price of generic drugs is only one tenth of that of patented drugs...

How can this make the original pharmaceutical company survive?

Fortunately, formal Indian generic drugs can be counter-sold by Europe and the United States through the evaluation of efficacy consistency, but they are drugs that have passed the patent protection period. Not only Europe and the United States, but also many imported ones in China.

Some of India's drugs that are still generic during the patent period, such as most cancer-targeted drugs can only be sold locally in India, and countries around the world will not import unauthorized generic drugs.

This allows original pharmaceutical companies to sell their patented drugs normally in countries other than India.

However, the Indian market basically doesn't expect it.

Pharmaceutical companies from all over the world have basically given up their sales in the Indian market, and it is impossible for anyone to beat Indian generic drugs in India.

But even so, there are still many cancer targeted drugs that smuggle from India to all over the world every year.

In addition to cancer-targeted drugs, India's vaccine development is also excellent.

India is a major vaccine supplier. Serum is India's largest vaccine company and the world's largest vaccine company. It can produce 2 billion vaccines a year, accounting for 60% of the world's total supply!

Moreover, Serum is investing 400 million US dollars to build a new assembly line, preparing to expand its production capacity by another billion.

The annual production capacity of all domestic vaccine companies is only at the level of more than one billion units.

If Ruikang Medical can find Indian vaccine companies to do OEM, its productivity will double compared to now.

But he dared not!

After the cardiomyocyte healing agent was launched globally, Indian vaccine production companies are trying to copy it!

His grandma's leg, cardiomyocyte healing agents are not actually very difficult to crack in reverse, or there are no drugs in the world that are difficult to crack in reverse!

Therefore, before the cardiomyocyte healing agent was launched, the Nandou Scientific Research Center applied for domestic and international patents.

It’s not OK to apply. If you don’t apply, any biomedical research and development institution can reversely crack the ingredients and production methods as long as it obtains a few tubes of cardiomyocyte healing agents and takes several months to one or two years!

That's what Indians do!

Nowadays, major vaccine manufacturers in India are thinking about imitating cardiomyocyte healing agents!

Ruikang's cancer-specific drugs are about to face this problem.

The cancer special drug is actually a special inactive vaccine made based on gene editing technology. You only need to reversely analyze the vaccine carrying a special genome to achieve imitation!
Chapter completed!